Funding Rounds
Enterome

Enterome Series F (2023, $3M)

Enterome

Cutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series F

Raised Amount: $3.17M

Investors